Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Update of genetic susceptibility in patients with Kawasaki disease

  • Yoon, Kyung Lim (Department of Pediatrics, Kyung Hee University Hospital at Gangdong)
  • Received : 2014.11.07
  • Accepted : 2015.02.20
  • Published : 2015.03.10
Download PDF
⟨ Previous Next ⟩

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis that predominantly affects children, and can result in coronary artery lesions (CAL). A patient with KD who is resistant to treatment with intravenous immunoglobulin (IVIG) has a higher risk of developing CAL. Incomplete KD has increased in prevalence in recent years, and is another risk factor for the development of CAL. Although the pathogenesis of KD remains unclear, there has been increasing evidence for the role of genetic susceptibility to the disease since it was discovered in 1967. We retrospectively reviewed previous genetic research for known susceptibility genes in the pathogenesis of KD, IVIG resistance, and the development of CAL. This review revealed numerous potential susceptibility genes including genetic polymorphisms of ITPKC, CASP3, the transforming growth factor-${\beta}$ signaling pathway, B lymphoid tyrosine kinase, FCGR2A, KCNN2, and other genes, an imbalance of Th17/Treg, and a range of suggested future treatment options. The results of genetic research may improve our understanding of the pathogenesis of KD, and aid in the discovery of new treatment modalities for high-risk patients with KD.

Keywords

References

  1. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J 2014; 33:24-7. https://doi.org/10.1097/INF.0000000000000010
  2. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012;22:216-21. https://doi.org/10.2188/jea.JE20110126
  3. Sonobe T, Kiyosawa N, Tsuchiya K, Aso S, Imada Y, Imai Y, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007;49:421-6. https://doi.org/10.1111/j.1442-200X.2007.02396.x
  4. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RS. Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr 2012;171:657-62. https://doi.org/10.1007/s00431-011-1631-2
  5. Sudo D, Monobe Y, Yashiro M, Mieno MN, Uehara R, Tsuchiya K, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012;171:651-6. https://doi.org/10.1007/s00431-011-1630-3
  6. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008;27:155-60.
  7. Burns JC. Commentary: translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967. Pediatr Infect Dis J 2002; 21:993-5. https://doi.org/10.1097/00006454-200211000-00002
  8. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010;20: 302-7. https://doi.org/10.2188/jea.JE20090180
  9. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Parents with a history of Kawasaki disease whose child also had the same disease. Pediatr Int 2011;53:511-4. https://doi.org/10.1111/j.1442-200X.2010.03267.x
  10. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22:79-85. https://doi.org/10.2188/jea.JE20110131
  11. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008;40:35-42. https://doi.org/10.1038/ng.2007.59
  12. Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 2010;19:2898-906. https://doi.org/10.1093/hmg/ddq176
  13. Onouchi Y, Suzuki Y, Suzuki H, Terai M, Yasukawa K, Hamada H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2013;13:52-9. https://doi.org/10.1038/tpj.2011.45
  14. Kuo HC, Yang KD, Juo SH, Liang CD, Chen WC, Wang YS, et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One 2011; 6:e17370. https://doi.org/10.1371/journal.pone.0017370
  15. Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, et al. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J Hum Genet 2011;56: 161-5. https://doi.org/10.1038/jhg.2010.154
  16. Kuo HC, Hsu YW, Wu CM, Chen SH, Hung KS, Chang WP, et al. A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki disease. PLoS One 2013;8:e69685. https://doi.org/10.1371/journal.pone.0069685
  17. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol 2010;162:131-7. https://doi.org/10.1111/j.1365-2249.2010.04236.x
  18. Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 2011;4:16-25.
  19. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007;74:196-206. https://doi.org/10.1016/j.cardiores.2007.02.008
  20. Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, Mohler ER 3rd, et al. Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg 2007;83:946-53. https://doi.org/10.1016/j.athoracsur.2006.10.026
  21. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008;9:194-202. https://doi.org/10.1038/ni1549
  22. Choi YM, Shim KS, Yoon KL, Han MY, Cha SH, Kim SK, et al. Transforming growth factor beta receptor II polymorphisms are associated with Kawasaki disease. Korean J Pediatr 2012;55:18-23. https://doi.org/10.3345/kjp.2012.55.1.18
  23. Cho JH, Han MY, Cha SH, Jung JH, Yoon KL. Genetic polymorphism of SMAD5 is associated with Kawasaki disease. Pediatr Cardiol 2014;35:601-7. https://doi.org/10.1007/s00246-013-0826-x
  24. Lee YC, Kuo HC, Chang JS, Chang LY, Huang LM, Chen MR, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet 2012;44:522-5. https://doi.org/10.1038/ng.2227
  25. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012;44:517-21. https://doi.org/10.1038/ng.2220
  26. Chang CJ, Kuo HC, Chang JS, Lee JK, Tsai FJ, Khor CC, et al. Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLoS One 2013; 8:e72037. https://doi.org/10.1371/journal.pone.0072037
  27. Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011;43:1241-6. https://doi.org/10.1038/ng.981
  28. Kim JJ, Park YM, Yoon D, Lee KY, Song MS, Lee HD, et al. Identification of KCNN2 as a susceptibility locus for coronary artery aneurysms in Kawasaki disease using genome-wide association analysis. J Hum Genet 2013;58:521-5. https://doi.org/10.1038/jhg.2013.43
  29. Lv YW, Wang J, Sun L, Zhang JM, Cao L, Ding YY, et al. Understanding the pathogenesis of Kawasaki disease by network and pathway analysis. Comput Math Methods Med 2013;2013:989307.
  30. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6. https://doi.org/10.1067/mpd.2000.104815
  31. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  32. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
  33. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113: 2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  34. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010;11:31-46. https://doi.org/10.1038/nrg2626
  35. Desai AN, Jere A. Next-generation sequencing: ready for the clinics? Clin Genet 2012;81:503-10. https://doi.org/10.1111/j.1399-0004.2012.01865.x
  36. Baird PN, Hageman GS, Guymer RH. New era for personalized medicine: the diagnosis and management of age-related macular degeneration. Clin Experiment Ophthalmol 2009;37:814-21. https://doi.org/10.1111/j.1442-9071.2009.02136.x
  37. Wurtman RJ. Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits. Metabolism 2013;62 Suppl 1:S27-9. https://doi.org/10.1016/j.metabol.2012.08.025
  38. Morse BL, Kim RB. Is personalized medicine a dream or a reality? Crit Rev Clin Lab Sci 2015;52:1-11. https://doi.org/10.3109/10408363.2014.950407
  39. Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, et al. Intrinsic cancer subtypes-next steps into personalized medicine. Cell Oncol (Dordr) 2015 Jan 14. [Epub]. http://dx.doi.org/10.1007/s13402-014-0203-7.

Cited by

  1. Use of corticosteroids during acute phase of Kawasaki disease vol.4, pp.4, 2015, https://doi.org/10.5409/wjcp.v4.i4.135
  2. Pediatric vasculitis vol.28, pp.1, 2015, https://doi.org/10.1097/bor.0000000000000236
  3. The Clinical Profile of Kawasaki Disease in Algerian Children: A Single Institution Experience vol.62, pp.2, 2016, https://doi.org/10.1093/tropej/fmv090
  4. Dissecting Kawasaki disease: a state-of-the-art review vol.176, pp.8, 2017, https://doi.org/10.1007/s00431-017-2937-5
  5. Pathogenetic determinants in Kawasaki disease: the haematological point of view vol.21, pp.4, 2015, https://doi.org/10.1111/jcmm.12992
  6. The Development and Researches of the Pathogenesis of Kawasaki Disease Animal Models vol.5, pp.1, 2015, https://doi.org/10.12677/jps.2017.51001
  7. Kawasaki disease: etiopathogenesis and novel treatment strategies vol.13, pp.3, 2015, https://doi.org/10.1080/1744666x.2017.1232165
  8. Quercetin Inhibits Inflammasome Activation by Interfering with ASC Oligomerization and Prevents Interleukin-1 Mediated Mouse Vasculitis vol.7, pp.None, 2015, https://doi.org/10.1038/srep41539
  9. Identification of differentially expressed microRNAs in acute Kawasaki disease vol.17, pp.1, 2015, https://doi.org/10.3892/mmr.2017.8016
  10. Molecular basis of coronary artery dilation and aneurysms in patients with Kawasaki disease based on differential protein expression vol.17, pp.2, 2015, https://doi.org/10.3892/mmr.2017.8111
  11. Lack of association between miR-218 rs11134527 A>G and Kawasaki disease susceptibility vol.38, pp.3, 2015, https://doi.org/10.1042/bsr20180367
  12. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase vol.44, pp.1, 2018, https://doi.org/10.1186/s13052-018-0536-3
  13. Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children vol.9, pp.None, 2015, https://doi.org/10.1038/s41598-019-51137-5
  14. Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease vol.62, pp.4, 2015, https://doi.org/10.3345/kjp.2019.00150
  15. Prevalence of Kawasaki Disease in a Tertiary Care Hospital: A Descriptive Cross-sectional Study vol.57, pp.220, 2015, https://doi.org/10.31729/jnma.4746